ClinPGx Blog (Page 36)

Sign in Subscribe

More issues

Russ Altman: Year In Review at AMIA Summit on Translational Bioinformatics 2014

Russ Altman presented the Year In Review yesterday at the AMIA Summit on Translational Bioinformatics 2014 in San Francisco. Dr. Altman's year in review is meant as an overview for trends and publications for the previous year and to speculate about what opportunities might lie in the year

Biocuration 2014 Toronto

PharmGKB Scientific Curators Ellen McDonagh and Julia Barbarino are attending the Biocuration 2014 conference in Toronto. On Monday 7th April, in a talk and poster presentation they will outline the PharmGKB curation process: how we curate PGx literature and interpret this for the clinic in the form of our Clinical

Dr. Michelle Whirl-Carrillo promoted to Associate Director of PharmGKB

PharmGKB is delighted to announce the promotion of Dr. Michelle Whirl-Carrillo to Associate Director. Dr. Whirl-Carrillo joined PharmGKB in 2002 as the project's first Scientific Curator. After briefly leaving PharmGKB to join the DTC genotyping start-up 23andMe, she returned in 2009 as the Assistant Director. We congratulate Michelle

New PharmGKB VIP Summary: SLC22A1 (OCT1)

Solute carrier family 22 (organic cation transporter), member 1 (SLC22A1, also called OCT1) is a polyspecific cationic transporter mediating the uptake of many organic cations from the blood into epithelial cells. It is predominantly expressed in the liver and plays a critical role in the hepatic uptake of many commonly

Canadian pharmacogenomics group recommends genetic testing for patients prescribed carbamazepine

In a recent article published online in the journal Epilepsia, the Canadian Pharmacogenomics Network for Drug Safety (CPNDS) has recommended genetic testing for the alleles HLA-B*15:02 and HLA-A*31:01 in all carbamazepine-naive patients before initiation of treatment. In patients who test positive for either of these alleles,

American Society of Health-System Pharmacists to host live webinar on CPIC

The American Society of Health-System Pharmacists (ASHP) will be hosting a live webinar on Tuesday, April 15th from 2:00 - 3:00 pm EST discussing the Clinical Pharmacogenetics Implementation Consortium (CPIC). The webinar will be presented by Kelly E. Caudle, CPIC coordinator at St. Jude Children's Research

Additional CFTR variants for ivacaftor treatment approved by FDA

The drug label for ivacaftor was recently amended and has been approved by the FDA. Ivacaftor was originally indicated only for use in Cystic Fibrosis patients with one or two copies of the G551D variant within the CFTR gene. In the amended ivacaftor drug label, the indication has been changed

CPIC guideline for ivacaftor therapy based on CFTR genotype of cystic fibrosis patients

Cystic fibrosis (CF) therapy has traditionally been based on the treatment of symptoms and infections, rather than targeting the underlying defect caused by variants in the CFTRgene. Ivacaftor is the first FDA-approved drug to specifically target a particular defect of the CFTR protein. It is indicated for use in patients

CPIC abacavir & HLA-B guideline update published

CPIC has extensively reviewed the literature and concluded no changes are required to the therapeutic recommendations of the abacavir dosing guideline based on HLA-B genotype since the original publication in 2012. The 2014 update includes the following additions: * Clinical implementation resources to help implementation of the guidelines into an Electronic

The Uncertain Future of Genetic Testing

<!-- /* Font Definitions */ @font-face {font-family:Cambria; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:auto; mso-font-pitch:variable; mso-font-signature:3 0 0 0 1 0;} /* Style Definitions */ p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-parent:""; margin:0in; margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:12.